Lymphoma / Leukemia / Myeloma News From Medical News Today Latest Health News and Medical News posted throughout the day, every day.
Seaweed Extract May Hold Promise For Non-Hodgkin's Lymphoma Treatment
Seaweed extract may eventually emerge as a lymphoma treatment, according to laboratory research presented at the second AACR Dead Sea International Conference on Advances in Cancer Research: From the Laboratory to the Clinic, held here March 7-10, 2010...
2010 Recipient Of Minority Scholar Award Will Conduct Clinical Research On Leukemia
Alison Walker, MD, has been selected to receive the ASH-AMFDP Award, and will begin her research in acute myeloid leukemia in July of this year...
Infectious Virus Hidden In Chromosomes During Latency Can Be Passed From Parents To Children
Human herpesvirus 6 (HHV-6) infects nearly 100 percent of humans in early childhood, and the infection then lasts for the rest of a person's life...
Key Cause Of Chronic Leukemia Progression Identified By Study
Researchers have discovered a key reason why a form of leukemia progresses from its more-treatable chronic phase to a life-threatening phase called blast crisis. The study, led by cancer researchers at the Ohio State University Comprehensive Cancer Center-Arthur G. James Cancer Hospital and Richard J...
NICE Set To Recommend Rituximab For Relapsed Or Refractory Chronic Lymphocytic Leukaemia
The National Institute for Health and Clinical Excellence (NICE) has today (4 March) issued final draft guidance recommending the drug rituximab(MabThera) as a treatment for certain patients with relapsed or refractory chronic lymphocytic leukaemia...
NICE Appraisal Of Azacitidine For Myelodysplastic Syndromes
The National Institute for Health and Clinical Excellence (NICE) is currently appraising the use of azacitidine (Vidaza, Celgene) for myelodysplastic syndromes...
Targeting Leukaemia Cell's Gene 'addiction' Presents New Strategy For Treatment
An international team of scientists studying acute forms of Leukaemia have identified a new drug target to inhibit the genes which are vital for the growth of diseased cells. The research, reported in EMBO Molecular Medicine, reveals how leukaemia cells become 'addicted' to genes, which if targeted could prevent diseased cells from developing...
FDA Sets March 22 For ODAC Meeting To Review CTI's New Drug Application For Pixantrone
Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) announced that the U.S. Food and Drug Administration's ("FDA") Oncologic Drugs Advisory Committee ("ODAC") will review CTI's New Drug Application ("NDA") for pixantrone for the treatment of relapsed/refractory aggressive non-Hodgkin's lymphoma ("NHL") on March 22, 2010...
ARIAD Receives Orphan Drug Designations For Its Investigational Pan BCR-ABL Inhibitor, AP24534, In Chronic Myeloid Leukemia
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) announced that its investigational pan-BCR-ABL inhibitor, AP24534, has been granted orphan drug designation by both the U. S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). In the U.S...
U.S. Food And Drug Administration (FDA) Sets 22 March For Oncologic Drugs Advisory Committee (ODAC) Meeting To Review OMAPROâ„¢
ChemGenex Pharmaceuticals Limited (ASX:CXS) announced that the U.S. Food and Drug Administration (FDA) has rescheduled the previously postponed Oncologic Drugs Advisory Committee (ODAC) meeting to 22 March 2010...
Over-Expression Of Gene Regulator Spurs Development Of Leukemia In Babies With Down Syndrome
Between 5 and 10 percent of babies with Down syndrome develop a transient form of leukemia that usually resolves on its own. However, for reasons that haven't been clear, 20 to 30 percent of these babies progress to a more serious leukemia known as Down syndrome acute megakaryoblastic leukemia (DS-AMKL), which affects the blood progenitor cells that form red blood cells and platelets...
Overcoming Multidrug Resistance In Acute Lymphoblastic Leukemia Cells
Acute lymphoblastic leukemia (ALL) most commonly affects children, in whom there is an overall cure rate of 85%. A strong predictor of poor outcome is resistance to chemotherapy with glucocorticoids. Such resistance is caused, at least in part, by an inability of the leukemic cells to die by a process known as mitochondrial apoptosis...
Children And Teens Less Likely Than Young Adults To Die Of Non-Hodgkin's Lymphoma
Young adults diagnosed with non-Hodgkin's lymphoma appear to have a higher risk of dying from the disease than do children and teens. Eric Tai, M.D...
New Cancer Treatment Gives Hope To Lymphoma And Leukemia Patients
Cancer researchers have high hopes for a new therapy for patients with certain types of lymphoma and leukemia. PCI-32765 is a new drug being assessed in a Phase I clinical trial at the Virginia G. Piper Cancer Center in collaboration with the Clinical Division of the Translational Genomics Research Institute (TGen)...
Cells Of Aggressive Leukemia Hijack Normal Protein To Grow
Researchers have found that one particularly aggressive type of blood cancer, mixed lineage leukemia (MLL), has an unusual way to keep the molecular motors running. The cancer cells rely on the normal version of an associated protein to stay alive. MLL happens when a piece of chromosome 11 breaks off at the normal MLL-associated gene...
Vion Pharmaceuticals Receives Response From FDA On Special Protocol Assessment For Onrigin(TM)
VION PHARMACEUTICALS, INC. (OTC Bulletin Board: VIONQ) announced that it had received a response from the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment ("SPA") for its oncology therapeutic Onriginâ„¢ (laromustine) Injection...
Sunesis Poised For Phase 3 Trial Of Voreloxin In Acute Myeloid Leukemia After Completing Formal End-of-Phase 2 Meetings With FDA
Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) announced that it has completed formal End-of-Phase 2 meetings with the U.S. Food and Drug Administration (FDA) related to its lead compound, voreloxin, in acute myeloid leukemia (AML). Sunesis has received feedback and guidance from the FDA in response to proposed plans for further development of voreloxin in the treatment of AML...
New Cancer-Fighting Strategy Focuses On Signaling Molecules
Cancer researchers studying the immune system have identified a previously unrecognized set of targets and biomarkers to battle solid tumors. The findings center on discovery of signaling molecules that are major players in a biochemical mechanism linking certain actions of B cells to solid tumor growth...
Mathematical Model Gives New Hope To Chronic Myeloid Leukaemia Patients
Doctors can now understand better chronic myeloid leukaemia (CML), including how it responds to therapy, thanks to a new mathematical model for the disease, developed by scientists in Portugal, Belgium and the United States...
Doubling Of Childhood Leukemia Rates In Southern Iraq Confirmed By International Study
Childhood leukemia rates have more than doubled over the last 15 years in the southern Iraq province of Basrah, according to the study, "Trends in Childhood Leukaemia in Basrah, Iraq (1993-2007), published in the American Journal of Public Health...
Novartis Drug Tasigna® Receives FDA Priority Review For Newly Diagnosed Patients With Early-stage Chronic Myeloid Leukemia
Novartis announced that Tasigna® (nilotinib) has been granted priority review by the US Food and Drug Administration (FDA) for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase...
US FDA Approves Rituxan/MabThera For The Most Common Type Of Adult Leukemia
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the US Food and Drug Administration (FDA) approved Rituxan/MabThera (rituximab) plus fludarabine and cyclophosphamide (FC) chemotherapy for people with either previously untreated (first-line) or previously treated (relapsed or refractory) CD20-positive chronic lymphocytic leukemia (CLL)...
Novartis Drug Tasigna(R) Receives FDA Priority Review For Newly Diagnosed Patients With Early-Stage Chronic Myeloid Leukemia
Novartis announced that Tasigna® (nilotinib) 200 mg capsules has been granted priority review by the US Food and Drug Administration (FDA) for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase...
FDA Approves Rituxan Plus Chemotherapy For The Most Common Type Of Adult Leukemia
Genentech, Inc., a wholly owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), and Biogen Idec (Nasdaq: BIIB) announced today the U.S. Food and Drug Administration (FDA) approved Rituxan® (rituximab) in combination with fludarabine and cyclophosphamide (FC) for people with previously untreated and previously treated CD20-positive chronic lymphocytic leukemia (CLL)...
Discovery Of Genetic Link To Leukemias With An Unknown Origin
Although leukemia is one of the best studied cancers, the cause of some types is still poorly understood. Now, a newly found mutation in acute myeloid leukemia patients could account for half of the remaining cases of adult acute leukemia with an unknown origin...
Worlds Best Pharmacy
canadian meds shop
Why is your product so cheap? How do you ship orders? We accept : Visa, MasterCard, AmEx, Diners and JCB cards. |
